SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sbpgroup.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
LANOVA MEDICINES PRESENTED PRELIMINARY CLINICAL DATA ON MK-2010/LM-299 AT AACR 2026

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that preliminary clinical data for MK-2010/LM-299, an investigational PD-1/VEGF bispecific antibody, were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026.

MK-2010/LM-299 was being independently developed by LaNova Medicines Limited ("**LaNova**"), a wholly-owned subsidiary of the Group. In November 2024, LaNova entered into a global exclusive licensing agreement with Merck & Co., Inc., Rahway, N.J., USA (known as "**MSD**" outside the United States and Canada), granting MSD exclusive global rights to develop, manufacture and commercialize LM-299.

MK-2010/LM-299 is an investigational tetravalent bispecific antibody targeting both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF), designed in an IgG-VHH fusion format with Fcγ silencing. Therapeutic strategies combining PD-1 inhibition and VEGF blockade – either through combination regimens or bispecific antibodies – have shown clinical efficacy across multiple advanced solid tumors.

Abstract No.: CT057/17

Title: Preliminary Results From the First-in-Human Study of MK-2010, a PD-1xVEGF Bispecific Antibody

Key safety and efficacy highlights (Phase 1/2 study):

- A total of 112 patients were treated across dose-escalation (n=40) and NSCLC expansion cohorts (n=72), including a heavily pretreated population (68% prior therapy; 60% prior anti-PD-(L)1; 26% prior anti-VEGF).

- MK-2010/LM-299 demonstrated a manageable safety profile, with no grade 5 treatment-related adverse events (TRAEs) observed and with one TRAE leading to discontinuation (in the dose escalation cohort). In the NSCLC expansion cohort, the safety profile was characterized by predominantly low-grade treatment-related adverse events (TRAEs), with limited Grade 3–4 TRAEs (17–27%) and no treatment-related deaths; VEGF inhibitor–associated toxicities were manageable and largely Grade 3 or below.

- Early signs of promising anti-tumor activity were observed in the study, with an unconfirmed overall response rate (ORR) in the NSCLC backfill cohort of 55% in the 20 mg/kg Q3W group and 44% in the 30 mg/kg Q3W group for previously untreated participants.

- Pharmacokinetic analysis showed a mean estimated half-life of approximately 9.5-12.6 days.

At a dose level of 20 mg/kg Q3W in first-line treatment of patients with NSCLC, MK-2010/LM-299 demonstrated an ORR of 55% with grade ≥3 TRAEs of 17%. These early data suggest MK-2010/LM-299 has a manageable safety profile across tested dose levels and shows early evidence of promising anti-tumor activity. These data support further development of MK-2010/LM-299 as both monotherapy and in combination settings.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 19 April 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.